03 Oct 2014
A study published in the BMJ suggests that long-acting insulin analogues are safer, more effective and more cost-effective than intermediate-acting therapies for adults with type 1 diabetes, but the difference in HbA1c is minimal. Healio
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024